Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide.

Date publication

octobre 2020

Journal

Acta oncologica (Stockholm, Sweden)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BERCEANU Ana , Pr DECONINCK Eric , Dr DAGUINDAU Etienne

Tous les auteurs :
Chevallier P, Berceanu A, Peterlin P, Garnier A, Le Bourgeois A, Imbert BM, Daguindau E, Mahé B, Dubruille V, Blin N, Touzeau C, Gastinne T, Lok A, Tessoulin B, Vantyghem S, Desbrosses Y, Bressollette C, Duquesne A, Eveillard M, Le Bris Y, Dormoy A, Malugani C, Deconinck E, Moreau P, Le Gouill S, Béné MC, Guillaume T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33112687

Résumé

The impact of acute graft versus host disease (GVHD) on survivals for patients receiving a haploidentical allogeneic stem-cell transplant (Allo-SCT) with peripheral blood stem-cells (PBSC) complemented by post-transplant cyclophosphamide (PTCY) is ill-known.

Mots clés

ATG, Allogeneic stem cell transplantation, GVHD, PBSC, PTCY, RIC, clofarabine, haplo-identical, immune

Référence

Acta Oncol. 2020 Oct 28;:1-9